CPA6

May be involved in the proteolytic inactivation of enkephalins and neurotensin in some brain areas. May convert inactive angiotensin I into the biologically active angiotensin II (PubMed:18178555). Releases a C-terminal amino acid, with preference for large hydrophobic C-terminal amino acids and shows only very weak activity toward small amino acids and histidine.

Suitable for use in Western Blot, Immunohistochemistry and ELISA. Other applications not tested.

Western Blot: 1:1000-1:3000, incubate membrane with diluted antibody in TBS, 5% milk, 0.1% Tween20 at 4°C with gentle shaking, overnight.
Immunohistochemistry: 1:200
ELISA (peptide): 1:20,000-1:40,000
Optimal dilutions to be determined by the researcher.

May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Pab

IgG

rabbit

human

~1mg/ml

Supplied as a liquid in PBS, pH 7.4, 0.02% sodium azide, 50% glycerol.

Purified by immunoaffinity chromatography.

Synthetic peptide corresponding to human CPA6. Species sequence homology

Recognizes endogenous levels of total human CPA6. Species Crossreactivity

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.